Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00572169 · ClinicalTrials.gov registry record · Phase 3
UARK 2006-66, Total Therapy 3B: An Extension of UARK 2003-33 Total Therapy
A Phase 3 study of Multiple Myeloma, sponsored by University of Arkansas.
- Active
- Registry status
- Phase 3
- Development phase
- 177
- Enrollment target
- 1
- Study location
NCT00572169: Active Phase 3 study of Multiple Myeloma, sponsored by University of Arkansas.
NCT00572169 is a Phase 3 study of Multiple Myeloma that is active but no longer recruiting, run by University of Arkansas. The registered enrollment target is 177 participants, below the 546-participant average among 438 other Multiple Myeloma trials with a reported enrollment target (68% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00572169, a Phase 3 study of Multiple Myeloma, is active but no longer recruiting, sponsored by University of Arkansas.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 3
- Development phase
- 177 participants
- Enrollment target
- 1
- Study location
Study Summary
With this study - Total Therapy IIIB - researchers are extending the findings of Total Therapy III based what they have learned from the first two studies (Total Therapy I and II), with new research strategies designed to explore why chromosome abnormalities found in persons with multiple myeloma affect the outcome of drug therapy used in this disease."
Conditions Studied
Interventions
- DRUG Cisplatin
- DRUG Dexamethasone
- DRUG Thalidomide
- DRUG Velcade
- DRUG Adriamycin
Study Locations (1)
Arkansas
- University of Arkansas for Medical Sciences/Myeloma Institute - Little Rock
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 177 participants |
| Start Date | 2006-11 |
| Est. Completion | 2027-08 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00572169
The ClinicalTrials.gov registry entry for NCT00572169 describes a study currently listed as active not recruiting, categorized as Phase 3. The registered enrollment target is 177 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 546-participant average among 438 other Multiple Myeloma trials with a reported enrollment target (68% lower). The listed sponsor is University of Arkansas, which has 318 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Multiple Myeloma appearing as the primary indexed condition, and to 5 interventions - of which Cisplatin is the first listed.
NCT00572169 reports 1 study location spanning 1 distinct geographic area - top geographies include Arkansas.
Frequently Asked Questions
What is clinical trial NCT00572169 about?
NCT00572169 is a clinical study titled "UARK 2006-66, Total Therapy 3B: An Extension of UARK 2003-33 Total Therapy". With this study - Total Therapy IIIB - researchers are extending the findings of Total Therapy III based what they have learned from the first two studies (Total Therapy I and II), with new research strategies designed to explore why chromosome abnormalities found in persons with multiple myeloma af...
What is the current status of trial NCT00572169?
This trial is currently active not recruiting. It is a Phase 3 study. The enrollment target is 177 participants. The study started on 2006-11. Estimated completion is 2027-08.
What conditions does trial NCT00572169 study?
This clinical trial studies the following conditions: Multiple Myeloma.
What interventions are being tested in trial NCT00572169?
The interventions under investigation include: Cisplatin (DRUG), Dexamethasone (DRUG), Thalidomide (DRUG), Velcade (DRUG), Adriamycin (DRUG).
Who is sponsoring clinical trial NCT00572169?
This trial is sponsored by University of Arkansas, which has 318 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00572169 being conducted?
This trial has 1 study location across Arkansas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Multiple Myeloma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Olanzapine 2.5 vs 5 mg in Quadruplet Nausea/Vomiting Prophylaxis Before High-Dose Melphalan
RECRUITING · Phase 3
-
A Study to Learn About the Study Medicine Elranatamab Alone and With Daratumumab in People With Multiple Myeloma Who Have Received Other Treatments
RECRUITING · Phase 3
-
A Study to Compare Iberdomide Maintenance Versus Lenalidomide Maintenance Therapy Following Autologous Stem Cell Transplant in Participants With Newly Diagnosed Multiple Myeloma
RECRUITING · Phase 3
-
Phase 3 Study of Teclistamab in Combination With Lenalidomide and Teclistamab Alone Versus Lenalidomide Alone in Participants With Newly Diagnosed Multiple Myeloma as Maintenance Therapy Following Autologous Stem Cell Transplantation
RECRUITING · Phase 3
-
Study Assessing Activity of Intravenous (IV) Etentamig Monotherapy Versus Standard Available Therapies in Adult Participants With Relapsed or Refractory Multiple Myeloma
RECRUITING · Phase 3
-
A Study Comparing JNJ-79635322 and an Anti-B-cell Maturation Antigen (BCMA)xCD3 Bispecific Antibody in Participants With Relapsed or Refractory Multiple Myeloma
RECRUITING · Phase 3
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.